Longeveron Mesenchymal Stem Cells (LMSCs)

BIOLOGICAL3 trials

Sponsors

Longeveron Inc.

Conditions

ARDS, HumanAging FrailtyCovid19

Phase 1

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

CompletedNCT02982915

Longeveron Inc.Aging Frailty

Start: 2016-11-30End: 2022-09-30Updated: 2022-11-04

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

Active, not recruitingNCT04629105

Longeveron Inc.ARDS, Human, Covid19

Start: 2020-07-24End: 2025-07-31Target: 70Updated: 2024-02-20

Phase 2

Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

CompletedNCT03169231

Longeveron Inc.Aging Frailty

Start: 2017-07-06End: 2021-09-30Updated: 2022-03-07

Related Papers

Clinical Study of Mesenchymal Stem/Stromal Cell Therapy for the Treatment of Frailty: A Proposed Experimental Design for Therapeutic and Mechanistic Investigation

The Journals of Gerontology Series A2021-10-283 citations